Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

CLSA Downgrades Waterdrop to Outperform

CLSA downgrades Waterdrop (NYSE:WDH) from Buy to Outperform.

byBenzinga Newsdesk

December 2, 2021

1 minute read

CLSA downgrades Waterdrop (NYSE:WDH) from Buy to Outperform.

Cassava Sciences Announces Completion of Dosing In Open-Label Study Of Simufilam For Alzheimer’s Disease

By Benzinga Newsdesk

Today, 7:37 AM

Outside Biostatisticians with Specific Expertise in Alzheimer's Disease Will Conduct an Independent Statistical Analysis on The Clinical Dataset. Clinical Dataset May Be Announced Approximately Year-End 2022,

SAVA

Papa John’s Q4 Earnings Beat Estimates Include A Decline In Sales

By Shivani Kumaresan

Today, 7:37 AM

Papa John's International, Inc. (NASDAQ: PZZA) reported fourth quarter FY22 sales decline of 0.5% year-on-year to $526.2 million, beating the analyst consens

PZZA

Citigroup Maintains Neutral on FMC, Lowers Price Target to $109

By Benzinga Newsdesk

Today, 7:37 AM

Citigroup analyst PJ Juvekar maintains FMC (NYSE:FMC) with a Neutral and lowers the price target from $118 to $109.

FMC

AbbVie Reports Positive CHMP Opinion For Risankizumab For Treatment Of Adults With Active Psoriatic Arthritis In EU

By Benzinga Newsdesk

Today, 7:37 AM

- CHMP positive opinion is based on data from two Phase 3 studies, KEEPsAKE-1 and KEEPsAKE-2[1],[2] - If approved, this will mark the second indication for risankizumab in the EU[3] - Psoriatic arthritis is a systemic

ABBV

CLSA Downgrades Waterdrop to Outperform

Related Posts

Cassava Sciences Announces Completion of Dosing In Open-Label Study Of Simufilam For Alzheimer’s Disease

Papa John’s Q4 Earnings Beat Estimates Include A Decline In Sales

Citigroup Maintains Neutral on FMC, Lowers Price Target to $109

AbbVie Reports Positive CHMP Opinion For Risankizumab For Treatment Of Adults With Active Psoriatic Arthritis In EU